Research Article
BibTex RIS Cite

Parkinson Hastalığında D Vitamini Düzeyinin Hastalık Şiddeti, Denge ve Düşme ile İlişkisi

Year 2022, Volume: 6 Issue: 3, 255 - 260, 25.12.2022
https://doi.org/10.46332/aemj.1033448

Abstract

Amaç: Parkinson hastalığında serum D vitamini düzeyleri ile hastalık şiddeti, denge sorunları ve düşme ve düşme korkusu arasındaki ilişkiyi değerlendirmek.

Araçlar ve Yöntem: Bu çalışma retrospektif, kesitsel olarak tasarlandı. Çalışmaya 45-80 yaş arası Parkinson hastaları ile sağlıklı kontroller dahil edildi. Çalışmanın sonuç ölçütleri, serum 25(OH) D vitamini seviyeleri, Hoehn&Yahr Ölçeği (HY), Birleşik Parkinson Hastalığı Derecelendirme Ölçeği-III (BPHDÖ-III), Berg denge ölçeği (BDÖ), Tinetti testi (TT) ve Uluslararası Düşme Etkinliği Ölçeği (DEÖ-U) idi.

Bulgular: Çalışmaya Parkinson hastalığı(PH) olan yetmiş iki katılımcı ve altmış sağlıklı kontrol dahil edildi. Yaş ortalaması, PH grubunda 67.4±8.3 yıl, kontrol grubunda 61.1±8.5 yıl idi. Ortalama 25(OH) D vitamini düzeyi PH grubunda 17.8±8.2 ng/ml, kontrol grubunda ise 22.2±9.7 ng/ml idi. Gruplar arasında 25(OH) D vitamini düzeyleri açısından istatistiksel olarak anlamlı fark vardı (p=0.005). PH grubundaki katılımcılar HY ölçeğine göre iki gruba ayrıldı (Erken evre grubu: Evre 1-2; İleri Evre grubu: Evre 3-4). Ortalama 25(OH) D vitamini düzeyi erken evre grupta 18,6±7,8 ng/ml iken ileri evre grupta 16,5±8,8 ng/ml idi. Her iki grupta da istatistiksel olarak anlamlı fark saptanmadı (p=0.299). Pearson analiz sonuçlarına göre PH grubunda, 25(OH) D vitamini düzeyleri, HY evreleri, BDÖ, TT, DEÖ-U ve BPHDÖ-III arasında korelasyon yoktu (p>0.05).

Sonuç: PH'da serum D vitamini düzeyleri sağlıklı kontrollere göre daha düşüktü. Ancak PH'da serum D vitamini düzeyleri ile hastalık şiddeti, denge sorunu ve düşme korkusu arasında anlamlı bir ilişki bulunamadı.

Supporting Institution

Destekleyen kurum bulunmamaktadır.

Project Number

Etik kurul no: KAEK/2021.11.287

References

  • 1. Peterson AL. A review of vitamin D and Parkinson's disease. Maturitas. 2014;78(1):40-44.
  • 2. Fullard ME, Duda JE. A Review of the Relationship Between Vitamin D and Parkinson Disease Symptoms. Front Neurol. 2020;11:454.
  • 3. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005;29(1):21-30.
  • 4. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 2002;13(3):100-105.
  • 5. Wion D, MacGrogan D, Neveu I, Jehan F, Houlgatte R, Brachet P. 1,25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J Neurosci Res. 1991;28(1):110-114.
  • 6. Shirazi HA, Rasouli J, Ciric B, Rostami A, Zhang GX. 1,25-Dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation. Exp Mol Pathol. 2015;98(2):240-245.
  • 7. Rimmelzwaan LM, van Schoor NM, Lips P, Berendse HW, Eekhoff EM. Systematic Review of the Relationship between Vitamin D and Parkinson's Disease. J Parkinsons Dis. 2016;6(1):29-37.
  • 8. Lv Z, Qi H, Wang L, et al. Vitamin D status and Parkinson's disease: a systematic review and meta-analysis. Neurol Sci. 2014;35(11):1723-1730.
  • 9. Larsson SC, Singleton AB, Nalls MA, Richards JB. No clear support for a role for vitamin D in Parkinson's disease: A Mendelian randomization study. Mov Disord. 2017;32(8):1249-1252.
  • 10. Peterson AL, Mancini M, Horak FB. The relationship between balance control and vitamin D in Parkinson's disease-a pilot study. Mov Disord. 2013;28(8):1133-1137.
  • 11. Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int. 2009;20(2):315-322.
  • 12. Sahin Alak ZY, Ates Bulut E, Dokuzlar O, Yavuz I, Soysal P, Isik AT. Long-term effects of vitamin D deficiency on gait and balance in the older adults. Clin Nutr. 2020;39(12):3756-3762.
  • 13. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020-1028.
  • 14. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41-47.
  • 15. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738-750.
  • 16. Berg K, Wood-Dauphinee S, Williams JI. The Balance Scale: reliability assessment with elderly residents and patients with an acute stroke. Scand J Rehabil Med. 1995;27(1):27-36.
  • 17. Sahin F, Yilmaz F, Ozmaden A, Kotevolu N, Sahin T, Kuran B. Reliability and validity of the Turkish version of the Berg Balance Scale. J Geriatr Phys Ther. 2008;31(1):32-37.
  • 18. Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986;34(2):119-126.
  • 19. Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C. Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing. 2005;34(6):614-619.
  • 20. Ulus Y, Durmus D, Akyol Y, Terzi Y, Bilgici A, Kuru O. Reliability and validity of the Turkish version of the Falls Efficacy Scale International (FES-I) in community-dwelling older persons. Arch Gerontol Geriatr. 2012;54(3):429-433.
  • 21. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930.
  • 22. Van den Bos F, Speelman AD, van Nimwegen M, et al. Bone mineral density and vitamin D status in Parkinson's disease patients. J Neurol. 2013;260(3): 754-760.
  • 23. Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V. High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol. 2011;68(3):314-319.
  • 24. Wang J, Yang D, Yu Y, Shao G, Wang Q. Vitamin D and Sunlight Exposure in Newly-Diagnosed Parkinson's Disease. Nutrients. 2016;8(3):142.
  • 25. Gökşenoğlu G, Topal K, Paker N, Buğdaycı D, Kesiktaş N. Vıtamin D defıciency and related factors in Ambulatory Patients with Mild To Moderate Parkinson's Disease. Turk Geriatri Derg. 2017;20(4): 289-295.
  • 26. Fidan F, Alkan BM, Tosun A. Çağın pandemisi: D vitamini eksikliği ve yetersizliği. Turk J Osteoporos. 2014;20(2):71-74.
  • 27. Çalış HT, Sütbeyaz ST, Sunkak S, et al. Parkinson Hastalarında D Vitamini Düzeyinin Osteoporotik Kırıklar ve Postür Bozukluğu ile İlişkilendirilmesi. Turk J Osteoporos. 2017;23:16-20.
  • 28. Mak MK, Wong-Yu IS, Shen X, Chung CL. Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat. Rev. Neurol. 2017;13(11):689-703.
  • 29. Dawson-Hughes B. Vitamin D and muscle function. J Steroid Biochem Mol Biol. 2017;173:313-316.
  • 30. Bischoff-Ferrari HA. Vitamin D in geriatric patients. Internist (Berl). 2020;61(6):535-540.

The Relationship of Vitamin D Levels with Disease Severity, Balance, and Falls in Parkinson’s Disease

Year 2022, Volume: 6 Issue: 3, 255 - 260, 25.12.2022
https://doi.org/10.46332/aemj.1033448

Abstract

Purpose: To evaluate the relationship between serum vitamin D levels with disease severity, balance problems and fear of falling in Parkinson’s disease.

Materials and Methods: This was a retrospective, cross-sectional study. Participants with Parkinson’s disease and healthy controls aged 45-80 years were included in the study. The outcomes of the study were serum 25(OH) vitamin D levels, Hoehn&Yahr Scale, Unified Parkinson’s Disease Rating Scale-III, Berg balance scale, Tinetti test, and International Falls Efficacy Scale scores.

Results: Seventy-two participants with Parkinson’s disease and sixty healthy controls were included in the study. The mean 25(OH) vitamin D level was 17.8±8.2 ng/ml in the PD group, while it was 22.2±9.7 ng/ml in the control group. There was a statistically significant difference in terms of 25(OH) vitamin D levels between the groups (p=0.005). The participants in the PD group were divided into two groups according to the HY scale scores (Early-stage group: Stage 1-2; Advanced-Stage group: Stage 3-4). The mean 25(OH) vitamin D level was 18.6±7.8 ng/ml in the early-stage group, it was 16.5±8.8 ng/ml in the advanced-stage group. No statistically significant differences were identified in both groups (p=0.299). There was no correlation between 25(OH) vitamin D levels, HY stages, BBS, TT, FES-I, and UPDRS-III in PD group (p>0.05).

Conclusion: Vitamin D levels were lower in PD than that in healthy controls. However, no significant relationship was found between vitamin D levels and disease severity, balance problem, and fear of falling in PD.

Project Number

Etik kurul no: KAEK/2021.11.287

References

  • 1. Peterson AL. A review of vitamin D and Parkinson's disease. Maturitas. 2014;78(1):40-44.
  • 2. Fullard ME, Duda JE. A Review of the Relationship Between Vitamin D and Parkinson Disease Symptoms. Front Neurol. 2020;11:454.
  • 3. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005;29(1):21-30.
  • 4. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 2002;13(3):100-105.
  • 5. Wion D, MacGrogan D, Neveu I, Jehan F, Houlgatte R, Brachet P. 1,25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J Neurosci Res. 1991;28(1):110-114.
  • 6. Shirazi HA, Rasouli J, Ciric B, Rostami A, Zhang GX. 1,25-Dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation. Exp Mol Pathol. 2015;98(2):240-245.
  • 7. Rimmelzwaan LM, van Schoor NM, Lips P, Berendse HW, Eekhoff EM. Systematic Review of the Relationship between Vitamin D and Parkinson's Disease. J Parkinsons Dis. 2016;6(1):29-37.
  • 8. Lv Z, Qi H, Wang L, et al. Vitamin D status and Parkinson's disease: a systematic review and meta-analysis. Neurol Sci. 2014;35(11):1723-1730.
  • 9. Larsson SC, Singleton AB, Nalls MA, Richards JB. No clear support for a role for vitamin D in Parkinson's disease: A Mendelian randomization study. Mov Disord. 2017;32(8):1249-1252.
  • 10. Peterson AL, Mancini M, Horak FB. The relationship between balance control and vitamin D in Parkinson's disease-a pilot study. Mov Disord. 2013;28(8):1133-1137.
  • 11. Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int. 2009;20(2):315-322.
  • 12. Sahin Alak ZY, Ates Bulut E, Dokuzlar O, Yavuz I, Soysal P, Isik AT. Long-term effects of vitamin D deficiency on gait and balance in the older adults. Clin Nutr. 2020;39(12):3756-3762.
  • 13. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020-1028.
  • 14. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41-47.
  • 15. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18(7):738-750.
  • 16. Berg K, Wood-Dauphinee S, Williams JI. The Balance Scale: reliability assessment with elderly residents and patients with an acute stroke. Scand J Rehabil Med. 1995;27(1):27-36.
  • 17. Sahin F, Yilmaz F, Ozmaden A, Kotevolu N, Sahin T, Kuran B. Reliability and validity of the Turkish version of the Berg Balance Scale. J Geriatr Phys Ther. 2008;31(1):32-37.
  • 18. Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986;34(2):119-126.
  • 19. Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C. Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing. 2005;34(6):614-619.
  • 20. Ulus Y, Durmus D, Akyol Y, Terzi Y, Bilgici A, Kuru O. Reliability and validity of the Turkish version of the Falls Efficacy Scale International (FES-I) in community-dwelling older persons. Arch Gerontol Geriatr. 2012;54(3):429-433.
  • 21. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930.
  • 22. Van den Bos F, Speelman AD, van Nimwegen M, et al. Bone mineral density and vitamin D status in Parkinson's disease patients. J Neurol. 2013;260(3): 754-760.
  • 23. Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V. High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol. 2011;68(3):314-319.
  • 24. Wang J, Yang D, Yu Y, Shao G, Wang Q. Vitamin D and Sunlight Exposure in Newly-Diagnosed Parkinson's Disease. Nutrients. 2016;8(3):142.
  • 25. Gökşenoğlu G, Topal K, Paker N, Buğdaycı D, Kesiktaş N. Vıtamin D defıciency and related factors in Ambulatory Patients with Mild To Moderate Parkinson's Disease. Turk Geriatri Derg. 2017;20(4): 289-295.
  • 26. Fidan F, Alkan BM, Tosun A. Çağın pandemisi: D vitamini eksikliği ve yetersizliği. Turk J Osteoporos. 2014;20(2):71-74.
  • 27. Çalış HT, Sütbeyaz ST, Sunkak S, et al. Parkinson Hastalarında D Vitamini Düzeyinin Osteoporotik Kırıklar ve Postür Bozukluğu ile İlişkilendirilmesi. Turk J Osteoporos. 2017;23:16-20.
  • 28. Mak MK, Wong-Yu IS, Shen X, Chung CL. Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat. Rev. Neurol. 2017;13(11):689-703.
  • 29. Dawson-Hughes B. Vitamin D and muscle function. J Steroid Biochem Mol Biol. 2017;173:313-316.
  • 30. Bischoff-Ferrari HA. Vitamin D in geriatric patients. Internist (Berl). 2020;61(6):535-540.
There are 30 citations in total.

Details

Primary Language English
Subjects Clinical Sciences
Journal Section Original Articles
Authors

Merve Damla Korkmaz 0000-0003-2422-5709

Project Number Etik kurul no: KAEK/2021.11.287
Early Pub Date December 13, 2022
Publication Date December 25, 2022
Published in Issue Year 2022 Volume: 6 Issue: 3

Cite

APA Korkmaz, M. D. (2022). The Relationship of Vitamin D Levels with Disease Severity, Balance, and Falls in Parkinson’s Disease. Ahi Evran Medical Journal, 6(3), 255-260. https://doi.org/10.46332/aemj.1033448
AMA Korkmaz MD. The Relationship of Vitamin D Levels with Disease Severity, Balance, and Falls in Parkinson’s Disease. Ahi Evran Med J. December 2022;6(3):255-260. doi:10.46332/aemj.1033448
Chicago Korkmaz, Merve Damla. “The Relationship of Vitamin D Levels With Disease Severity, Balance, and Falls in Parkinson’s Disease”. Ahi Evran Medical Journal 6, no. 3 (December 2022): 255-60. https://doi.org/10.46332/aemj.1033448.
EndNote Korkmaz MD (December 1, 2022) The Relationship of Vitamin D Levels with Disease Severity, Balance, and Falls in Parkinson’s Disease. Ahi Evran Medical Journal 6 3 255–260.
IEEE M. D. Korkmaz, “The Relationship of Vitamin D Levels with Disease Severity, Balance, and Falls in Parkinson’s Disease”, Ahi Evran Med J, vol. 6, no. 3, pp. 255–260, 2022, doi: 10.46332/aemj.1033448.
ISNAD Korkmaz, Merve Damla. “The Relationship of Vitamin D Levels With Disease Severity, Balance, and Falls in Parkinson’s Disease”. Ahi Evran Medical Journal 6/3 (December 2022), 255-260. https://doi.org/10.46332/aemj.1033448.
JAMA Korkmaz MD. The Relationship of Vitamin D Levels with Disease Severity, Balance, and Falls in Parkinson’s Disease. Ahi Evran Med J. 2022;6:255–260.
MLA Korkmaz, Merve Damla. “The Relationship of Vitamin D Levels With Disease Severity, Balance, and Falls in Parkinson’s Disease”. Ahi Evran Medical Journal, vol. 6, no. 3, 2022, pp. 255-60, doi:10.46332/aemj.1033448.
Vancouver Korkmaz MD. The Relationship of Vitamin D Levels with Disease Severity, Balance, and Falls in Parkinson’s Disease. Ahi Evran Med J. 2022;6(3):255-60.

Ahi Evran Medical Journal  is indexed in ULAKBIM TR Index, Turkish Medline, DOAJ, Index Copernicus, EBSCO and Turkey Citation Index. Ahi Evran Medical Journal is periodical scientific publication. Can not be cited without reference. Responsibility of the articles belong to the authors.

    Creative Commons Lisansı

This journal is licensed under the Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı.